Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study

AIMS: To evaluate the efficacy and safety of mirabegron in children and adolescents (aged 3 to <18 years) with neurogenic detrusor overactivity (NDO) using clean intermittent catheterization. METHODS: In this open‐label, multicenter, baseline‐controlled, Phase III study (NCT02751931), participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Baka‐Ostrowska, Małgorzata, Bolong, David T., Persu, Cristian, Tøndel, Camilla, Steup, Achim, Lademacher, Christopher, Martin, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361978/
https://www.ncbi.nlm.nih.gov/pubmed/34058027
http://dx.doi.org/10.1002/nau.24657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361978/
https://www.ncbi.nlm.nih.gov/pubmed/34058027
http://dx.doi.org/10.1002/nau.24657

Ejemplares similares